Compare stocks

ASML Holding N.V. (ASML) vs Applied Materials, Inc. (AMAT) vs Lam Research Corporation (LRCX)

ASML pairs the strongest growth and quality with the highest multiples; AMAT and LRCX are cheaper but more volatile

The three semiconductor equipment makers show a clear split. ASML leads Qanvo's scorecard on growth (100), profitability and quality (83), earnings momentum (83), technical momentum (90) and lower risk (100), but is the most expensive, with a forward P/E of 24.81× against 19.60× for AMAT and 21.04× for LRCX. Valuation has no clear leader, since AMAT (67) and LRCX (58) are within 10 points. LRCX leads on balance-sheet resilience (80), while AMAT scores lowest of the group on quality (0) and trails on growth (12). All three have fallen sharply over 3 months (ASML -13.0%, LRCX -27.4%, AMAT -28.7%) and sit below their 200-day averages.

Business overview

All three companies are US-listed Technology names in the Semiconductors industry, and all describe themselves as suppliers of semiconductor manufacturing equipment, so the business models are broadly similar rather than materially different. ASML is the largest by market cap at $585.51B, roughly double AMAT at $295.79B and LRCX at $278.18B; all three are in the Mega tier. By profile description, ASML focuses on lithography, metrology and inspection systems for memory and logic chipmakers, including EUV and DUV lithography. AMAT provides materials engineering and wafer fabrication tools through two segments, Semiconductor Systems and Applied Global Services. LRCX supplies processing equipment with a deposition focus. ASML is Netherlands-domiciled and reports in EUR; AMAT and LRCX are US-domiciled and report in USD. Geographic mix is disclosed for AMAT and LRCX only: China is 30.07% of AMAT's fiscal 2025 revenue and 33.83% of LRCX's fiscal 2026 revenue. A comparable ASML geographic split is not in the facts. Services are 22.51% of AMAT revenue (Applied Global Services) versus 35.93% for LRCX (Customer Support and Other).

  • ASML's $585.51B market cap is roughly double AMAT's $295.79B and LRCX's $278.18B.
  • China is 33.83% of LRCX revenue versus 30.07% for AMAT, a concentration shared by both.
  • Services-type revenue is 35.93% at LRCX versus 22.51% at AMAT.

Valuation

On Qanvo's valuation scorecard there is no clear leader: AMAT (67) and LRCX (58) are within 10 points, and ASML (25) trails the group. ASML is the most expensive on most multiples: trailing P/E 38.70×, forward P/E 24.81×, price/sales 13.21× and EV/EBITDA 31.14×. AMAT shows 31.48×, 19.60×, 9.53× and 25.33×; LRCX shows 28.56×, 21.04×, 9.62× and 23.56×. Forward P/E is based on analysts' estimates. PEG is similar for ASML (0.65×) and AMAT (0.63×), with LRCX at 0.82×. Free-cash-flow yield is highest at ASML (4.05%), then LRCX (3.11%) and AMAT (1.56%), so ASML's premium is partly offset on cash generation. Against its own history, AMAT's trailing P/E of 31.48× sits above its 5-year median of 20.53× and within a range of 10.95× to 65.91×. ASML and LRCX have no 5-year P/E history because statements are in EUR while shares trade in USD. Against sector peers, ASML's forward P/E is at the 71st percentile (sector median 18.80×), LRCX at the 57th and AMAT at the 52nd. ASML's premium coincides with the strongest growth, quality and lowest-risk scores in the group; AMAT's lower multiples coincide with the lowest quality score.

  • ASML's trailing P/E of 38.70× compares with 31.48× for AMAT and 28.56× for LRCX.
  • Forward P/E is 19.60× for AMAT, 21.04× for LRCX and 24.81× for ASML, all analyst-estimate based.
  • ASML's free-cash-flow yield of 4.05% is above LRCX at 3.11% and AMAT at 1.56%.
  • AMAT's trailing P/E of 31.48× is above its 5-year median of 20.53×.

Growth

ASML leads the growth scorecard with 100, versus LRCX at 38 and AMAT at 12. Reported revenue growth over the last year is 29.57% for ASML, 29.42% for LRCX and 9.45% for AMAT. Last-quarter revenue growth is 55.16% at ASML, 34.04% at AMAT and 24.68% at LRCX. Over three years the pace is slower: revenue compounds at 15.55% for ASML, 8.05% for LRCX and 3.23% for AMAT. EPS growth over the last year is 42.54% at LRCX, 35.64% at AMAT and 53.02% at ASML, with 3-year EPS CAGRs of 20.48% (ASML), 11.55% (LRCX) and 5.19% (AMAT). The quarterly history shows ASML revenue rising from $7.52B-equivalent levels in Q3 FY2025 to 11.66B in Q3 FY2026 (EUR), and LRCX rising from 5.34B to 8.22B over its latest quarters. AMAT moved from 7.01B to 9.12B. Fiscal years differ and currencies differ, so compare rates, not amounts. Analysts' estimates for next-year EPS growth are 38.18% for ASML, 31.25% for AMAT and 25.56% for LRCX. These are opinions, not reported results.

  • ASML's last-quarter revenue growth of 55.16% compares with 34.04% for AMAT and 24.68% for LRCX.
  • Three-year revenue CAGR is 15.55% for ASML versus 3.23% for AMAT, showing AMAT's recent pickup is from a slower base.
  • Analysts expect next-year EPS growth of 38.18% at ASML, 31.25% at AMAT and 25.56% at LRCX.

Profitability, cash flow & financial health

On profitability and quality, ASML leads Qanvo's scorecard with a score of 83, ahead of LRCX at 67 and AMAT at 0 (the lowest of the group, not weak in absolute terms). Operating margin is nearly level between LRCX at 38.76% and ASML at 38.55%, with AMAT at 31.53%. ASML's gross margin is highest at 54.34%, versus 52.04% for LRCX and 49.61% for AMAT. Net margin runs 34.14% for ASML, 33.67% for LRCX and 30.26% for AMAT. Cash conversion separates them most. ASML's FCF margin is 53.56%, LRCX's 29.86% and AMAT's 14.88%. AMAT's free cash flow growth is -18.92% year over year, while LRCX is at 113.02%. ROIC is 106.47% for ASML, 98.31% for LRCX and 32.58% for AMAT; ROE is 85.36% for LRCX, 65.64% for ASML and 40.82% for AMAT. Over the past year operating margin rose 4.62 points at ASML, 4.28 at LRCX and 2.31 at AMAT, so growth is feeding better economics at all three. Statements are in different currencies (ASML in EUR), so compare ratios, not amounts. On the balance sheet, LRCX leads resilience with a score of 80 versus 50 for ASML and 20 for AMAT. Net debt/EBITDA is -0.66× for ASML, -0.28× for LRCX and -0.16× for AMAT, all net cash. Debt/equity is 0.09× for ASML, 0.27× for LRCX and 0.29× for AMAT. Current ratio is 2.48× for LRCX, 2.42× for AMAT and 1.49× for ASML.

  • ASML's FCF margin of 53.56% is well above LRCX at 29.86% and AMAT at 14.88%.
  • LRCX's operating margin of 38.76% is marginally above ASML's 38.55%, with AMAT lower at 31.53%.
  • ASML carries the lowest debt/equity at 0.09×, against 0.27× for LRCX and 0.29× for AMAT.
  • LRCX has the highest current ratio at 2.48×, versus 1.49× for ASML.

Shareholder returns & capital allocation

Dividends are small at all three and not a main part of the story. Dividend yield is 0.62% for ASML, 0.53% for AMAT and 0.50% for LRCX. Payout ratios are modest: 24.02% for ASML, 16.84% for AMAT and 14.34% for LRCX, leaving most earnings for reinvestment or buybacks. Dividend growth over three years is strongest at AMAT with 20.39%, then LRCX at 14.96% and ASML at 3.58%. Streaks differ: LRCX has 11 years of dividend growth, AMAT 8 and ASML 2. Share counts fell at ASML (-1.06% over one year) and LRCX (-0.12%), while AMAT's rose 0.25%. ASML's last annual report showed -5.95B of repurchases against -2.55B of dividends. AMAT showed -4.89B and -1.38B, and LRCX -3.85B and -1.27B. Amounts are in EUR for ASML and USD for the others, so compare the mix, not the size. In all three, buybacks exceeded dividends. Recent news adds to this: LRCX announced a $25 Billion share repurchase authorization on Nov 5, 2026, and ASML reported transactions under its buyback program in the past week.

  • AMAT's three-year dividend growth of 20.39% is above LRCX at 14.96% and ASML at 3.58%.
  • ASML's payout ratio of 24.02% is the highest of the group, versus 14.34% for LRCX.
  • ASML's share count fell 1.06% over a year, while AMAT's rose 0.25%.
  • LRCX has the longest dividend growth streak at 11 years, against 8 for AMAT and 2 for ASML.

Earnings intelligence

Over the last four reported quarters, ASML beat EPS consensus in three of them: 20.13% (Oct 14, 2026), 10.03% (Jul 15) and 8.50% (Apr 15), with a miss of -3.03% on Jan 28. AMAT beat in each of its last four: 2.94% (Aug 13), 6.72%, 7.69% and 2.84%, and its EPS beat streak is 18. LRCX beat by 0.92% (Oct 21), 7.69% (Jul 29), 8.09% (Apr 22) and 8.55% (Jan 28). Some LRCX entries show extreme negative surprises (for example -99.53%) with EPS actuals and consensus on a different scale, so these are excluded. Stock reactions diverged from the beats. ASML moved -3.01%, 2.74%, -4.80% and -2.10%. AMAT moved -7.47%, 0.00%, 4.42% and -3.27%. LRCX moved -12.64%, 10.43%, 0.07% and 4.07%. Next dates: AMAT reports Nov 12, 2026 (not confirmed), with an implied move of 12.33%; ASML and LRCX are both estimated at Jan 27, 2027. Analyst EPS revisions over 30 days are 7.77% for ASML, 1.72% for LRCX and 0.15% for AMAT. Qanvo's earnings momentum scorecard puts ASML ahead (83), then AMAT (50) and LRCX (17). No guidance figures appear in the facts for the three, apart from a news headline that ASML raised 2026 guidance, with no numbers.

  • ASML's latest EPS surprise of 20.13% is the largest of the group, against 2.94% for AMAT and 0.92% for LRCX.
  • AMAT has the longest beat streak at 18, versus 3 for ASML and 1 for LRCX.
  • LRCX fell -12.64% after its latest report, the largest drop of the three, despite a 0.92% EPS beat.
  • ASML's 30-day EPS revision of 7.77% is well above AMAT's 0.15%.

Technicals, relative performance & risk

Price returns by period, from the ranking: over 1 month ASML -13.8% leads AMAT -25.1% and LRCX -28.2%; over 3 months ASML -13.0%, LRCX -27.4%, AMAT -28.7%; over 6 months ASML -3.7%, AMAT -16.0%, LRCX -24.9%. Over 1 year AMAT 58.5% leads ASML 45.2% and LRCX 33.7%, while over 3 and 5 years LRCX leads (230.2% and 267.1%) ahead of AMAT and ASML. Total returns, including dividends, are close to price returns, for example 1-year 59.4% for AMAT, 45.8% for ASML and 34.3% for LRCX. All three trade below their 20-, 50- and 200-day averages. ASML is -4.40%, -9.70% and -5.83% from them, AMAT -4.45%, -15.58% and -16.45%, and LRCX -7.72%, -20.91% and -21.70%. AMAT and LRCX both show a death cross (Nov 6 and Nov 9, 2026). RSI(14) is 42.61 for ASML, 41.95 for AMAT and 39.77 for LRCX. Versus the 52-week high, ASML is -24.61%, AMAT -49.64% and LRCX -49.28%. Relative strength rating: ASML 83, AMAT 59, LRCX 36. Risk is lowest for ASML: beta 1.68, 30-day volatility 53.57%, 1-year drawdown -31.81%. AMAT shows 2.83, 75.48% and -55.84%; LRCX 3.32, 85.87% and -57.26%. Weak charts for AMAT and LRCX sit against fundamentals showing 1-year revenue growth of 9.45% and 29.42% respectively, so price and fundamentals are in tension.

  • ASML's 3-month return of -13.0% is less than half the declines of LRCX (-27.4%) and AMAT (-28.7%).
  • LRCX trails on relative strength rating at 36, versus 83 for ASML and 59 for AMAT.
  • LRCX is -21.70% below its 200-day average, against -5.83% for ASML.
  • Beta of 3.32 for LRCX compares with 1.68 for ASML, and its 1-year drawdown is -57.26%.

Analyst & ownership sentiment

Analyst opinion is positive across all three, though the depth differs. As of Nov 10, 2026, AMAT has 1 Strong Buy, 42 Buy, 12 Hold and 0 Sell ratings; LRCX has 39 Buy, 10 Hold and 1 Sell; ASML has 21 Buy, 15 Hold and 3 Sell. ASML therefore has the largest share of Hold and Sell ratings. These are analysts' opinions, not outcomes. Mean targets are given only for AMAT ($636.15, 70.76% above the price) and LRCX ($367.42, 65.21% above). Both were set when prices were far higher, and several recent target changes were cuts. Over 30 days, estimates for ASML's EPS were revised up 7.77%, against 1.72% for LRCX and 0.15% for AMAT. Ownership filings lag by weeks. Institutional ownership is 84.27% for AMAT and 86.52% for LRCX, up 4.37% and 5.45% over three months; the facts give no figure for ASML. AMAT and LRCX insiders were net sellers in the last 90 days, with 3 sells (-4.5M) at AMAT and 7 sells (-29.4M) at LRCX; ASML shows no insider activity. Short float is 0.35% for ASML, 1.79% for AMAT and 2.26% for LRCX.

  • ASML's EPS estimates rose 7.77% over 30 days, ahead of LRCX at 1.72% and AMAT at 0.15%.
  • AMAT's mean analyst target of $636.15 implies 70.76% upside versus 65.21% for LRCX; ASML's facts give no mean target.
  • LRCX insiders had 7 sales totalling -29.4M net in 90 days, versus 3 sales (-4.5M) at AMAT.
  • Short float is 2.26% at LRCX, 1.79% at AMAT and 0.35% at ASML.

Risks & catalysts

Volatility is the shared risk. Beta over one year is 3.32 for LRCX, 2.83 for AMAT and 1.68 for ASML, and the one-year maximum drawdown is -57.26%, -55.84% and -31.81% respectively. All three sit roughly 25% to 49% below their 52-week highs, and AMAT and LRCX both recorded death crosses in November. Qanvo's scorecard rates ASML as the lower-risk profile and LRCX as the strongest on balance-sheet resilience. Concentration and valuation also matter. China is 30.07% of AMAT's fiscal 2025 revenue and 33.83% of LRCX's fiscal 2026 revenue; the facts give no geographic split for ASML. ASML's forward P/E of 24.81 is 26.00% above the industry median of 19.69, and its estimates-based growth figures depend on analysts being right. AMAT's free-cash-flow yield is 1.56%, the lowest of the group. Catalysts: AMAT reports Nov 12, 2026 (not confirmed), with an implied move of 12.33%, about double its average past earnings move. AMAT goes ex-dividend Nov 19, 2026, and LRCX Dec 2, 2026. ASML and LRCX report next on Jan 27, 2027, both unconfirmed.

  • Beta is 3.32 at LRCX, 2.83 at AMAT and 1.68 at ASML.
  • Maximum one-year drawdown was -57.26% at LRCX and -55.84% at AMAT, against -31.81% at ASML.
  • China accounts for 33.83% of LRCX revenue and 30.07% of AMAT revenue; no ASML split is given.
  • AMAT's earnings on Nov 12, 2026 carry an implied move of 12.33%, versus a 6.13% eight-quarter average move.

Analysis written November 11, 2026. AI-generated, for information only; not investment advice.